Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Panbella Therapeutics third quarter 2024 earnings call. At this time, all participants are on a listen-only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. Joining me on today's call are Jennifer Simpson, Chief Executive Officer, and Sue Horvath, Chief Financial Officer. Before we begin, please note that statements made on this call that are not historical facts may be considered forward-looking statements. Risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements are detailed in the company's filings with the SEC. Any forward-looking statements made on this call speak only as of today's date, and the company does not undertake any obligation to update or revise any of these statements to reflect future events or circumstances. With that, I will turn the call over to the company's CEO, Jennifer Simpson. Dr. Simpson, please go ahead. Thank you, and thank you all for joining us. I will start today's call by highlighting our investment from Nant Capital and then discussing our clinical development program, our recent achievements, and upcoming milestones. After that, Sue will review our financial results before we open the call-up for Q&A. As mentioned, a significant recent development is our $12 million strategic loan commitment from NAP Capital. The loan consists of two tranches of convertible promissory notes. The first tranche was funded in the gross amount of $2.85 million on October 22nd, and the second tranche is expected to fund in a gross amount of $9.15 mill...